32,784 research outputs found
Oral History Interview with Fred K. Fox
No full textTranscript of an oral interview with Fred K. Fox. Fox served with Company K, 3rd Battalion, 1st Marines on Peleliu. He tells of his experiences on Peleliu when he landed and fought to take and hold a key piece of high ground. Fox also speaks of returning to Peleliu in the 1960s and thereafter
Oral History Interview with Fred K. Fox
No full textTranscript of an oral interview with Fred K. Fox. Fox served with Company K, 3rd Battalion, 1st Marines on Peleliu. He tells of his experiences on Peleliu when he landed and fought to take and hold a key piece of high ground. Fox also speaks of returning to Peleliu in the 1960s and thereafter
Person-centred advocacy: Some ethical issues
No full textIn the second of two articles on advocacy for people with dementia Mike Fox with Lesley Wilson considers some of the ethical issues arising from advocacy work within a residential home that was due to close
Preparation of Fox Valley Technical College faculty for multicultural education
No full textIncludes bibliographical references.The purpose of this study was to determine the level of preparedness of Fox Valley Technical College faculty for multicultural education. The demographics of the district population were changing rapidly, and faculty must be prepared to meet the needs of multicultural students. A survey was administered to full- and part-time faculty of Fox Valley Technical College. The survey was intended to collect data about levels of education and experience, perceived training needs, level of comfort with multicultural education and level of interest in further training. The data gathered was analyzed to determine the need for future training, training subjects, and the training formats preferred by faculty. The results of this research provide a basis on which to build future professional growth training at Fox Valley Technical College. The training for faculty will ensure higher success for both faculty and students
Kara Gust interviews prolific author and poet, retired Michigan State University Professor Hugh B. Fox
No full textProlific author and poet, retired Michigan State University Professor Hugh B. Fox talks about his early family life in Chicago and his writing career. Fox explains how he became acquainted with theater, music, and ballet at a young age and how he was forced into medical school, but later abandoned it to pursue the liberal arts and writing. Fox talks about his many interests including archeology, and his treatise on author and friend Charles Bukowski. Fox is interviewed by Kara Gust for the Michigan State University Libraries' Michigan Writers Series
Ralph Beebe
No full textDr. Ralph Beebe is a Quaker historian who has been associated with Newberg, George Fox College/University for many years. He is the author of several books that depict the history of Oregon Yearly Meeting and George College. Ralph Beebe is a strong pacifist, taking part in the Civil Rights movement and non-violent protests against the Vietnam war. Beebe holds and AB from GFU an MEd from Linfield, MA and PhD from Uof O. Taught high school history for 17years then 35 years at GFU now a professor emeritus. Beebe is the author of 8 books with more in the works. One of Beebe\u27s works was a 100 year history of George Fox University published for the 100 year anniversary of the college in 1991.https://digitalcommons.georgefox.edu/noteable_individuals/1069/thumbnail.jp
About the Author - from Counseling and the Demonic
No full textAbout the Author from Counseling and the Demonic by Rodger K Buffor
Peggy Fowler
No full textShortly after graduating from George Fox in 1973, Peggy Fowler embarked on a 35-year career at Portland General Electric that culminated with her promotion to CEO in 2000. Upon her retirement in 2009, she left as one of Portland’s most respected business figures, revered for her leadership atop one of the city’s flagship corporate entities and for her civic contributions as a member of several public and private boards and organizations. Fowler is credited with guiding PGE through the Enron era and for serving as a reassuring presence to employees, many of whom saw their 401(k)s devalued when Enron filed for bankruptcy. When the Portland Business Journal asked Oregon CEOs to identify the executive they most admire, Fowler’s “radical grace under pressure” made her the overwhelming choice in 2005. Fowler has also served on the George Fox Board of Trustees and the Oregon Independent College Foundation Board of Trustees.https://digitalcommons.georgefox.edu/noteable_individuals/1077/thumbnail.jp
Selective If inhibition:new frontiers inthe management of coronary disease
No full textTHE LAST 30 YEARS HAVE SEEN SPECTACULAR PROGRESS IN THE
management of stable coronary artery disease (CAD), with numerous
new pharmacological and interventional options becoming available.
The most recent statistics from the American Heart Association (AHA)
report a 33% reduction in rates of mortality due to CAD in the 10 years to 2004,1 which can be
largely attributed to these advances. Despite this progress, the disease remains an important
contributor to mortality and morbidity in the Western world. Indeed, the AHA statistics also place
CAD as the single largest killer of American adults, with 1 in 5 deaths being attributable to CAD.1
Clearly, there is little room for complacency in our management of stable CAD, and we need to
continue to seek original and innovative ways of saving lives in this population.
A striking demonstration of this situation came from analysis of data from patients included
in the REduction of Atherothrombosis for Continued Health (REACH) Registry in 44 countries
between 2003 and 2004.2 This 1-year, international study recruited a large subset of more than
38 000 patients with stable CAD. The majority of the REACH patients were receiving contemporary,
evidence-based, preventive drug therapy, including antiplatelet therapy, lipid-lowering agents,
and angiotensin-converting enzyme inhibitors, and about half were receiving β-blockers. Despite
this, all-cause mortality at 1 year was 2.89% and cardiovascular mortality was 1.93%. Patients
with stable CAD also had a 4.52% rate of a composite end point of cardiovascular death, myocardial
infarction (MI), and stroke. The REACH authors rightly concluded that continued efforts are
needed to improve secondary prevention and clinical outcomes.2 The implications of the REACH
data in terms of burden of disease are alarming, considering that the lifetime risk of developing
CAD for American adults aged over 40 is 49% for men and 32% for women.1 One conclusion is
that current management strategies in stable CAD are failing to reach the expectations of cardiologists
and patients alike.3
Current guidelines recommend a two-pronged management strategy for patients with stable
CAD, who require one treatment to relieve symptoms alongside another to reduce long-term morbidity
and mortality.4 Despite the progress in the field, 50% of patients remain symptomatic with
treatment, and rates of mortality are highly unsatisfactory. These shortcomings can be traced to
a number of factors. Pharmacological therapy is abound with problems of subtherapeutic dosing
and compliance. Furthermore, the optimization of treatment can be hindered by insufficient
efficacy in patients with refractory angina and by a long list of contraindications, for example,
β-blockers are contraindicated in patients with asthma, peripheral vascular disease, and severe
bradycardia, which may limit their use in those patient populations. Another factor is poor tolerability,
which may lead to treatment discontinuation and reduce the efficacy of even the most
rigorous management strategy.
Surgical intervention does not necessarily resolve these problems: intervention is not always
possible, and most revascularized patients still require antianginal treatment after the procedure.
Indeed, as the Clinical Outcomes Utilizing Revascularization and AGgressive drug Evaluation
(COURAGE) trial recently demonstrated,5 there is no benefit of percutaneous coronary interven-
E D I T O R I A L
Address for correspondence:
Prof Roberto Ferrari, Chair of
Cardiology, Arcispedale S. Anna,
University of Ferrara, Corso
Giovecca 203, 44100, Ferrara,
Italy and Fondazione Salvatore
Maugeri, IRCCS, Brescia, Italy
(e-mail [email protected])
Prof Kim Fox, Professor of
Cardiology, Royal Brompton
Hospital, London SW3 6NP, UK
(e-mail [email protected])
Medicographia.
2008;30:189-195.
Selective I
f inhibition:
new frontiers in the management
of coronary artery disease
b y R . F e r r a r i a n d K . F o x ,
I t a l y a n d U n i t e d K i n g d o m
Kim FOX, MD, FESC
Professor of Cardiology
Royal Brompton Hospital
London, UK
Roberto FERRARI, MD, PhD
Chair of Cardiology
Arcispedale S. Anna
University of Ferrara
and Fondazione Salvatore
Maugeri, IRCCS
Brescia, ITALY
tion (PCI) on top of guideline-based optimized pharmacological therapy, in terms of reduction
in risk of mortality, MI, or major cardiovascular events. This demonstrates how important it is
to raise our standards in preventive cardiology through improvement of established lifestyle and
therapeutic intervention and control of other clinical parameters, which can improve cardiovascular
risk assessment and management.
The ideal treatment for stable CAD would be one that provided both anti-ischemic and antianginal
efficacy, as well as improvement in prognosis by reducing cardiovascular events. Heart
rate (HR) is one of the clinical parameters that is most frequently assessed in daily practice. Being
the main determinant of ischemia, HR reduction is established as an important therapeutic
component of the prevention of ischemia. A strong association between elevated HR and increased
risk of all-cause mortality, cardiovascular mortality, and development of cardiovascular
disease has been shown in the general population, as well as in patients with hypertension, diabetes,
and CAD.6,7 Experimental data have demonstrated the involvement of HR in the development
of atherosclerosis with reduction in its progression after pharmacological or surgical HR
reduction. The impact of β-blockers and of some calcium blockers on mortality in post-MI patients
has been suggested to be related to reduction in resting HR. Consistent with this understanding
of the important role of HR, ivabradine, the first selective and specific If inhibitor, opens
up promising opportunities in the management of CAD
Compliance Update with Tom Fox
No full textJoin us for lunch with Tom Fox, compliance professional, author and creator of the Compliance Podcast Network, hosting a variety of compliance related podcasts, including a succinct daily compliance tip
- …
